NEW YORK – Oncocyte said on Thursday that it is collaborating with the Fondazione Michelangelo in Milan, Italy to evaluate the company's DetermaIO test as a therapy response predictor in the NeoTRIPaPDL1 trial.
DetermaIO is a tissue-based gene expression assay, designed to evaluate signals associated with the tumor immune microenvironment. The test stratifies patients according to their likelihood of responding to immunotherapy.